Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Witty Heralds Success Of New Sales Model, Reassures Over Advair

Executive Summary

GlaxoSmithKline isn't losing too much sleep over imminent generic competition in the US for Advair and CEO Andrew Witty explains why he expects biologics-like economic dynamics for the product. The CEO also outlined the measurable gains of GSK's new model for engaging with healthcare professionals at a media interaction in India.


Related Content

KOL Webinars Get Maximum Bang For Pharma's Digital Buck?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts